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to a subsequently diminished recruit-
ment of T cells. Tacrolimus could also
have a direct effect on CCR10 expres-
sion by T cells, as has been shown for
other immunosuppressive drugs (Moed
et al., 2004; Park et al., 2005; Caproni
et al., 2007). However, we were unable
to carry out these experiments.
In summary, our findings illustrate
that topical tacrolimus treatment has the
potential to reduce a CD4/CD8 T-cell-
mediated skin inflammatory process by
the downregulation of skin-specific
chemokines and chemokine receptors.
Informed consent was obtained from
parents regarding the use of photographs.
Institutional approval is provided to use
leftover biological material obtained for
diagnostic purposes for related research in
line with the Helsinki guidelines.
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Pemphigus Vulgaris in White Europeans Is Linked with
HLA Class II Allele HLA DRB1*1454 but Not DRB1*1401
Journal of Investigative Dermatology (2010) 130, 311–314; doi:10.1038/jid.2009.241; published online 22 October 2009
TO THE EDITOR
Population studies have consistently
shown a link between certain class II
HLA alleles and ethnic groups in patients
with pemphigus vulgaris (PV). In parti-
cular, HLA DRB1*04 and *14 and
DQB1*0503 and *0302 alleles (Tron
et al., 2005) have been shown to be
strongly associated with PV. Although
previous studies have suggested that PV
is associated with DRB1*1401 in a
number of populations from Europe andAbbreviation: PV, pemphigus vulgaris
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Table 1. HLA DRB1 and DQB1 allele frequencies in (a) white Europeans and (b) Indo-Asians with pemphigus
vulgaris and in matched controls1
(a)
WE allele count WE allele frequency % Significance
Allele Patients (n=96) Controls (n=100) Patients (n=96) Controls (n=100) P-value, OR, CI
DRB1
*0301 8 29 4.2 14.5 P=0.0009, OR 0.26, CI (0.1, 0.61)
*04 71 29 37.0 14.5 Po0.00001, OR 3.46, CI (2.06, 5.83)
*0402 52 0 27.1 0.0 Po0.00001, OR undefined
*0701 14 29 7.3 14.5 *P=0.034, OR 0.46, CI (0.22, 0.95)
*14 44 8 22.9 4.0 Po0.00001, OR 7.14, CI (3.11, 10.96)
*1401 2 0 1.0 0.0 NS
*1404 9 0 5.2 0.0 P=0.0009, OR 9.89, CI (1.27, 210.33)
*1454 32 8 16.7 4.0 P=0.00007, OR 4.8, CI (2.05, 11.65)
*15 8 25 4.2 12.5 P=0.005, OR 0.3, CI (0.12, 0.73)
DQB1
*02 19 51 9.9 25.5 P=0.0001, OR 0.32, CI (0.17, 0.59)
*0302 63 18 32.8 9.0 Po0.00001, OR 4.94, CI (2.7, 9.11)
*0303 3 13 1.6 6.5 *P=0.027, OR 0.23, CI (0.05, 0.87)
*0501 12 28 6.3 14.0 *P=0.018, OR 0.41, CI (0.19, 0.87)
*0503 43 8 22.4 4.0 Po0.00001, OR 6.93, CI (3.03, 16.48)
*0601 4 1 2.1 0.5 NS
*0602 6 23 3.1 11.5 *P=0.0029, OR 0.25, CI (0.09, 0.66)
(b)
IA allele count IA allele frequency % Significance
Patients (n=57) Controls (n=59) Patients (n=57) Controls (n=59) P-value, OR, CI
DRB1
*0301 1 17 0.9 14.4 P=0.0003, OR 0.05, CI (0.0, 0.38
*04 23 8 20.2 6.8 *P=0.002, OR 4.01, CI (1.54,10.8)
*0402 16 1 14.0 0.8 P=0.0003, OR 19.10, CI (2.59,393)
*0701 8 14 7.0 11.7 NS
*14 53 14 46.5 11.9 Po0.00001, OR 6.45, CI (3.16,13.35)
*1401 1 0 0.9 0.0 NS
*1404 48 8 42.1 6.8 Po0.00001, OR 10, CI (4.2, 24.5)
*1454 3 5 2.6 4.2 NS
*15 5 25 4.4 21.2 P=0.0003,OR 0.17, CI (0.05, 0.49)
DQB1
*02 7 30 6.1 25.4 P=0.0001, OR 0.19, CI (0.07, 0.49)
*0302 18 8 15.8 6.8 *P=0.049, OR 2.58, CI (1.0, 6.8)
*0303 2 2 1.8 1.7 NS
*0501 4 10 3.5 8.5 NS
*0503 54 15 47.4 12.7 Po0.00001, OR 6.18, CI (3.07, 12.57)
*0601 5 18 4.4 15.3 *P=0.011, OR 0.25, CI (0.08, 0.76)
*0602 0 3 0.0 2.5 NS
CI, confidence interval; IA, Indo-Asian; NS, not significant; OR, odds ratio; WE, white European. *P=not significant after Bonferonni correction.
1HLA DRB1 *0101, *0103, *0401, *0403, *0404, *0405, *0406, *0407,*0408, *0410, *08, *09, *10,*11,*12,*13, *1406/7,*1415,*1428, *16 and DQB1*0301,
*04, *0502, *0603, *0604 were also tested, but allele frequencies were not significantly different in either group compared with controls.
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Asia, including Italy (Lombardi et al.,
1999), France (Loiseau et al., 2000), and
Japan (Miyagawa et al., 1997), recent
data suggest that alleles previously clas-
sified as DRB1*1401 may actually
represent the novel allele DRB1*1454,
which was identified while exploring
sequence diversity in exon 3 of HLA
DRB1 (Horn et al., 2007) and was
assigned DRB1*1454 by the World
Health Organization Nomenclature
Committee in October 2005.
In this study, we sought to determine
HLA DRB1 (including DRB1*1454) and
DQB1 allele frequencies in PV patients
living in the United Kingdom from two
major ethnic groups:white Europeans
and Indo-Asians.
A total of 153 patients with PV—96
of white European (WE) descent and 57
Indo-Asians (IAs, from India, Bangla-
desh, Pakistan, Sri Lanka, and Tanza-
nia)—were recruited from two centers
in the United Kingdom. A cohort of
normal controls with no history of skin
or autoimmune disease were matched
on the basis of ethnic origin (100 WE,
59 IA). Medium- to high-resolution HLA
class II typing was performed using PCR
with sequence-specific primers on
DNA samples of patients and controls.
In addition, DRB1*14 subtyping was
performed on samples positive for
HLA-DRB1*14 using the Dynal AllSet
SSP DRB1*14 kit (Dynal Biotech, In-
vitrogen, Wirral, UK).
In both ethnic groups, HLA
DRB1*04 and *14 and DQB1*0503
and *0302 alleles were significantly
associated with PV (Table 1a and b),
consistent with the results of previous
studies (Tron et al., 2005). In WE
patients (Table 1a), HLA DRB1*0402
was the most significantly overex-
pressed allele, with a frequency of
27.1% in patients compared with 0%
in controls (Po0.00001, OR undefined).
In contrast to previous studies (Miyagawa
et al., 1997; Lombardi et al., 1999;
Loiseau et al., 2000), we could not
identify any association of DRB1*1401
with PV. However, the DRB1*1454
allele was significantly associated with
WE patients (P¼0.00007). Other sig-
nificantly overexpressed alleles in the
WE patient group included DRB1*1404
(P¼0.0009), DQB1*0302 (Po0.00001),
and DQB1*0503 (Po0.00001).
As with WE patients, we found
significantly higher frequencies of HLA
DRB1*0402 (P¼0.0003)* and *1404 (Po
0.00001) and DQB1*0503 (Po0.00001)
and *0302 (P¼0.049) alleles in IA PV
patients than in the IA control group
(Table 1b). Notably, DRB1*1404 was the
most significantly overexpressed allele
overall in IA patients (42.1% compared
with 6.8% in the IA controls). As in WE
patients, we could not identify any
association with HLA DRB1*1401.
However, DRB1*1454 was not observed
to a significant degree in IA PV patients.
In both ethnic groups, certain DRB1
and DQB1 alleles were in negative
association with PV, perhaps suggesting
a protective effect. In WE patients, there
was a significant decrease in the
DQB1*02 allele frequency in PV patients
(25.5% in controls, 9.9% in patients,
P¼ 0.0001) and in DRB1*0301
(P¼0.0009) in the WE control group. In
IA PV patients, there were also significant
reductions in DQB1*02 (P¼ 0.0001) and
DRB1*0301 (P¼0.0003) allele frequen-
cies compared with those in controls. In
addition, DRB1*15 also had a lower
frequency compared with controls
(P¼0.0003).
The DRB1 locus is highly poly-
morphic, with more than 300 alleles.
Horn et al. (2007) recently showed that
in some samples previously typed as
DRB1*1401, a different exon 3 se-
quence was identified, differing from
DRB1*1401 at nucleotide position 51
of exon 3. This results in a change of
codon 112 TAC to CAC, resulting in a
tyrosine-to-histidine exchange in the
transcribed protein. This allele has been
named DRB1*1454. Our data clearly
show that HLA DRB1*1454 is strongly
associated with PV in WE patients but
not in IA patients. We only found one
patient with HLA DRB1*1401 in the IA
patient group and two patients in the
WE patient group, despite this allele
having been reported numerous times
as being associated with PV in a
number of populations. It seems likely
that all the previously recognized asso-
ciations of pemphigus with DRB1*1401
are actually with DRB1*1454. Conven-
tional assays by PCR with sequence-
specific primers have typed DRB1*14
alleles on the basis of exon 2 and will
not have differentiated DRB1*1401 and
DRB1*1454. The use of exon 3 primers
now allows for a distinction of these
alleles, and we recommend that these
be used in future association studies.
However, it is unclear whether the
amino-acid change associated with
DRB1*1454 has an effect on the binding
of target antigens in pemphigus; further
work is necessary to elucidate this.
HLA DRB1*14 and *04 alleles were
the most significant alleles associated
with PV in both the IA and WE groups.
HLA DRB1*0402 was the strongest risk
factor in WE patients, whereas HLA
DRB1*1404 had the strongest associa-
tion in IA patients, underscoring the
important genetic differences between
these groups. Although HLA DQB1*
0503 was significantly associated with
PV in both groups, this may well be a
reflection of its linkage disequilibrium
with DRB1*14 alleles. Similarly,
DQB1*0302 is in linkage disequili-
brium with DRB1*04.
This study represents, to our knowl-
edge, the largest cohort of white Eur-
opean and Indo-Asian patients with PV
in whom class II HLA typing has been
published to date. We have confirmed
previously published associations with
the alleles HLA DRB1*0402 and 1404
and DQB1*0302 and 0503, with
DRB1*1404 being the strongest risk
factor in the IA group and DRB1*0402
being the strongest risk factor in the WE
group. We have also shown a signifi-
cant association with a novel allele,
DRB1*1454, in white European indivi-
duals with pemphigus vulgaris. Finally,
our data indicate that genetic suscept-
ibility differences in ethnic groups are
maintained in patients living away from
their countries of ethnic origin, under-
lining the importance of genetic risk
factors in this disease.
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Response to Imatinib Mesylate Depends on the Presence of
the V559A-Mutated KIT Oncogene
Journal of Investigative Dermatology (2010) 130, 314–316; doi:10.1038/jid.2009.197; published online 8 October 2009
TO THE EDITOR
Identification of markers that predict
the response to a targeted therapy is a
key goal for the treatment of melanoma.
A major advance was the observation
that certain subtypes, such as mucous
membrane melanoma and acral lenti-
ginous melanoma, are frequently asso-
ciated with activating mutations in the
KIT oncogene (Curtin et al., 2006).
Imatinib mesylate, a small-molecule in-
hibitor of protein tyrosine kinases, has
been used with considerable success in
the treatment of gastrointestinal stromal
tumors, which are induced by abnormal
activation and overexpression of the KIT
receptor in 90% of cases (Sleifjer et al.,
2008). Recent reports have described the
usefulness of this molecule in the treat-
ment of rectal (Hodi et al., 2008) and
acral lentiginous melanoma (Kim et al.,
2008). Here, we report a patient with a
rapid response to imatinib in a lung
metastasis from an acral lentiginous
melanoma. Surprisingly, this was paral-
leled by progressive disease of locore-
gional lymph node metastasis.
A 64-year-old woman was admitted
because of progressive severe dyspnea
at rest. A pulmonary mass obstructing
the left main bronchus was revealed
by computed tomographic scanning
(Figure 1a). Grayish pigmentation on
her left big toe revealed an acral
lentiginous melanoma. Computed tomo-
graphic imaging of the abdomen and
pelvis excluded visceral metastases but
revealed lymph node metastases in the
left ilioinguinal region (Figure 1b). Biopsy
specimens were excised from the skin
and lymph nodes and by incision via
endoluminal access from the pulmonary
mass. Probes were processed for routine
histology and immunohistochemistry
and preserved for molecular biology.
Our studies were conducted after obtain-
ing written informed consent and institu-
tional review board approval and were in
compliance with the Declaration of
Helsinki Principles.
Histopathology of the skin pigmen-
tation confirmed the diagnosis and
revealed parts of an acral lentiginous
melanoma (not shown). Histopathology
of both the lung (Figure 1c) and lymph
node (Figure 1d) biopsies showed
highly proliferative atypical epithelioid
cells. Expression analysis by immuno-
histochemistry using a specific mono-
clonal mouse antibody against KIT
(CD117) revealed that both metastases
showed the presence of KIT; however,
the lung specimen (Figure 1e) expressed
the protein more brightly and uniformly
than did the lymph node metastasis
(Figure 1f). Furthermore, S100, Melan-A,
and HMB-45 were positively stained in
both probes (Figures 1g and h). We
initiated monotherapy with imatinib
mesylate (Glivec, Novartis Pharma
Nu¨rnberg, Germany) 400 mg once dai-
ly. After 6 weeks, radiological reassess-
ment of the chest showed regression of
the pulmonary mass; the largest dia-
meter had decreased from 3.2 to
2.0 cm. Moreover, the atelectasis of
the left upper lobe had reversed com-
pletely (Figure 1i). The performance
status was remarkably improved.
However, the lymph node metastasis
in the left groin showed marked pro-
gression; the largest diameter had
increased from 3.0 to 5.8 cm in the
inguinal node (Figure 1j) and from 2 to
3 cm in the iliacal node (not shown).
In an effort to understand this differ-
ential biological behavior of the two
tumor manifestations, we investigated
the KIT mutation status of the primary
tumor, the lymph node, and the lung
metastases. To this end, genomic DNA
was extracted and exons 11, 13, 17,
and 18 of the KIT gene, which harbor
the vast majority of mutations identified
in human tumors, were analyzed by
PCR amplification followed by direct
sequencing. Interestingly, in both the
primary tumor and the lymph node
metastasis, we detected only wild-type
sequences, whereas in the lung metas-
tasis, a homo- or hemizygous nucleotideAbbreviation: CT, computed tomography
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